Strategic Acquisition FlowJo was acquired by Waters Corporation in February 2026 as part of Waters’ integration with BD Biosciences and Diagnostic Solutions, signaling expanded access to Waters’ global customer base and complementary analytics capabilities for flow cytometry and single-cell data.

Expansion Opportunities Post-acquisition, there is potential to cross-sell Waters’ analytical technologies and services to FlowJo’s user base, plus leverage FlowJo’s established software for flow cytometry and single-cell analysis to broaden Waters’ instrument and service ecosystem.

Technical Synergies FlowJo’s cloud and analytics track record (Envoy, SeqGeq, Omics workflows) suggests demand for integrated cloud-enabled data coordination, multi-omics pipelines, and scalable data analysis—areas where Waters BD diagnostics strengths could amplify customer value.

Customer Target FlowJo operates with a specialized user base in life sciences research, immunology, and phenotyping, presenting a clear path to engage biotech and academic labs adopting Waters’ instrumentation and informatics solutions.

Growth Readiness With a revenue range of 10–25 million and an 11–50 employee footprint, FlowJo appears agile and scalable for incremental investments in joint product development, training programs, and co-marketing to accelerate market adoption.